Advancements in Cubosomes: A Promising Platform for Targeted Anticancer Drug Delivery

Nanosized particles are stabilised by polymers and made mostly of amphiphilic lipids known as cubosomes (CUBs). Encapsulating hydrophilic, hydrophobic, and amphiphilic pharmaceuticals is made effective by their internal bi-continuous cubic phase architecture, which gives a high surface area and partitioned aqueous domains. These self-assembled nanoparticles exhibit thermodynamic stability, biocompatibility, and mucoadhesive properties, making them ideal carriers for diverse multiple administration routes, including oral, transdermal, parenteral, and ocular. Problems with medication solubility, bioavailability, and non-specific toxicity are some of the most important ones that CUBs aim to solve. This review presents a comprehensive overview of CUB structure, types, formulation methods, and characterization techniques. The review emphasizes recent advancements in CUB-based delivery of chemotherapeutic agents, including paclitaxel and doxorubicin, cisplatin, methotrexate, and 5-fluorouracil, highlighting their improved pharmacokinetics and reduced systemic toxicity Despite manufacturing challenges, ongoing research into scalable production and novel excipients continues to support their translational promise. CUBs represent a versatile and potent platform in nanomedicine, offering substantial improvements in drug delivery and cancer treatment. Recent advancements in formulation strategies and surface modification is further strengthened their therapeutic potential. Cubosomes as a promising platform in precision oncology and next generation cancer therapeutics.